Intuitive Surgical (Intuitive Surgical (ISRG)) had a rough Friday. The robotic surgery pioneer's stock plunged more than 13% to hit a new 52-week low, after the company delivered an earnings update that left investors wanting more. The headline: Intuitive reaffirmed its 2026 da Vinci procedure growth outlook, but the fine print revealed slowing U.S. procedure trends and insurance-related headwinds that spooked the market.
The company said U.S. procedure growth has moderated relative to recent trends and its own expectations at the start of the year, driven mainly by procedures that patients can defer. That's a polite way of saying that some patients are putting off surgeries, and it's showing up in the numbers.
China Competition and International Headwinds
CEO David Rosa painted a sobering picture of the operating environment in China. “In China, the environment remains challenging. We continue to see lower tender activity, increased domestic robotic competition, and policy-driven pricing pressure,” he said on the earnings call. Rosa added that the company is navigating policy changes, including charge code revisions and China's 15th Five-Year Plan quota process.
“We continue to operate through a dynamic policy environment, including charge code changes and the 15th Five-Year Plan quota process. We are engaging with provincial governments on the charge code policy and are progressing through the green channel process for both SP and Da Vinci 5. When cleared, these platforms will bring additional differentiated capabilities to Chinese customers and their patients,” Rosa said.
On a brighter note, Japan's new reimbursement policies supporting robotic surgery took effect on June 1, expanding coverage for additional procedures and providing incentives for higher utilization. So not all international news was bad.
US Procedure Growth Slows
CFO Jamie Samath pointed to the expiration of enhanced Affordable Care Act premium subsidies as a factor that affected some patients and contributed to softer procedure growth. “Patients impacted by the expiration of subsidies for ACA Enhanced premiums. Looking at benign procedures, a subset of which can be deferred, we saw a slight moderation in procedure growth rate that started in Q1. U.S. da Vinci Bariatric cases continued to feel the impact of rising GLP-1 usage, declining high single digits during the quarter,” Samath said.
In other words, the weight-loss drug boom is still eating into bariatric surgery volumes, and the end of ACA subsidies is making some patients think twice about elective procedures.
Analysts Cut Price Forecasts
Wall Street reacted swiftly. William Blair noted that Intuitive's more than 10% after-hours decline reflected elevated investor expectations rather than a deterioration in the company's long-term outlook. The brokerage said maintaining, rather than raising, its 2026 procedure growth guidance disappointed investors given the stock's premium valuation. It flagged several near-term headwinds: weaker ACA-related procedure volumes, intensifying competition in China, slowing growth as the business scales, and pricing initiatives that could heighten competitive concerns. Still, William Blair maintained its Outperform rating, citing Intuitive's industry-leading earnings growth profile.
Piper Sandler said U.S. procedure growth slowed by about 200 basis points sequentially and fell short of Wall Street expectations. Analyst Adam Maeder reiterated an Overweight rating but lowered the price forecast to $470 from $580. And he wasn't alone. A parade of firms cut their targets: JPMorgan to $450 from $550, Mizuho to $400 from $500, Wells Fargo to $487 from $654, TD Cowen to $485 from $520, Evercore ISI to $375 from $430, RBC Capital to $575 from $600, Stifel to $550 from $670, Citigroup to $500 from $590, Bernstein to $685 from $750, Leerink Partners to $454 from $573, Baird to $500 from $525, and BTIG to $469 from $512. That's 13 firms in total, all trimming their expectations.
Intuitive Surgical Price Action
As of Friday's publication, Intuitive Surgical shares were down 13.14% at $349.45, trading at a new 52-week low. The stock has lost nearly half its value from its highs, and the market is clearly reassessing the near-term outlook. But with many analysts still bullish long-term, the question is whether this is a buying opportunity or a sign of more pain ahead.
